RESEARCH MONOGRAPH · KDC-MN-137

Gonadorelin (GnRH)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

78/100

The native GnRH decapeptide is the pulsatile-axis tool the longer-acting agonists arent

Gonadorelin is just GnRH, the native hypothalamic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). The reason it matters as a distinct research tool from the long-acting GnRH agonists (leuprolide, goserelin, triptorelin) is the pulse profile. Endogenous GnRH is released in pulses every 60 to 90 minutes from the hypothalamus, and the gonadotrope response to pulsatile versus continuous stimulation is fundamentally different. Pulsatile drives LH/FSH release; continuous causes receptor desensitization and downstream suppression, which is why the long-acting agonists chemically castrate patients in prostate cancer and pediatric central precocious puberty.

So when you administer native gonadorelin in short pulses (clinically by infusion pump in hypogonadotropic hypogonadism patients), you recapitulate physiology. When you administer it as a long-acting depot, you get the opposite effect through receptor downregulation. The same molecule, opposite outcomes depending on dosing pattern. Thats genuinely useful pharmacology to understand.

What we like: this is the right tool for studying acute hypothalamic-pituitary-gonadal axis activation. Half-life of about 4 minutes means you can do pulse-protocol experiments cleanly. The receptor pharmacology is textbook well-mapped, GnRHR is a Gq-coupled GPCR with characterized signaling. And it's been used clinically in pulsatile fashion for decades in fertility contexts, so the safety profile is well-understood.

What we dont like: the 4-minute half-life means dosing is operationally annoying for any sustained-stimulation paradigm. You need pump infusion or frequent injection for any chronic study. People sometimes confuse gonadorelin with the long-acting agonists in the literature search, which leads to misinterpretation.

Sourcing: established decapeptide, easy to synthesize, easy to characterize. The N-terminal pyroglutamate and C-terminal amide are essential for activity and can be verified by mass spec. Reliable from reputable vendors.

Underappreciated as a research tool because most people interested in GnRH biology default to the long-acting agonists which arent useful for studying physiological pulsatile signaling. The native decapeptide is the right tool when pulsatility matters.

Evidence: 85
Mechanism: 88
Reliability: 80
Safety: 80
Sourcing: 85
Value: 75
Signal: 55
Staying power: 72

Plain-language summary Intrigue 60 / 100

Gonadorelin is the natural decapeptide GnRH (gonadotropin-releasing hormone) used in research and historical clinical applications for testing pituitary function. Pulsatile administration triggers normal LH and FSH release. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Decapeptide GnRH agonist

Synthetic gonadotropin-releasing hormone, used clinically for diagnostic GnRH stimulation testing and for stimulation of LH/FSH release.

Abstract

Gonadorelin (GnRH, LHRH; CAS 9034-40-6; molecular formula C55H75N17O13; molecular weight 1182.31) is the synthetic decapeptide form of gonadotropin-releasing hormone. The compound is FDA-approved (Factrel) for diagnostic GnRH stimulation testing of pituitary gonadotropin reserve. Pulsatile administration (every 90 minutes) produces physiological LH/FSH release; continuous administration produces receptor downregulation and gonadotropin suppression (the basis for the leuprolide/goserelin class of long-acting analogs used in prostate cancer and endometriosis). Pharmacokinetics: plasma half-life 2 to 4 minutes. Reported research dose ranges in the literature are described in the source publications. Research-grade applications use the compound for stimulation of endogenous gonadotropin release on testosterone restoration protocols.

Mechanism of action

GnRH receptor agonist; pulsatile administration stimulates LH/FSH release, continuous administration causes receptor downregulation.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-137

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Gonadorelin (GnRH)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs